Last reviewed · How we verify
NCT01598844: JUPITER
JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation
trial testing Transcatheter aortic valve replacement in Aortic Stenosis in 210 participants. Completed in 31 July 2018.
27 August 2015
Quick facts
| Lead sponsor | JenaValve Technology, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 210 |
| Start date | 30 May 2012 |
| Primary completion | 27 August 2015 |
| Estimated completion | 31 July 2018 |
| Sites | 15 locations across United Kingdom, Netherlands, Switzerland, Germany |
Drugs / interventions tested
- Transcatheter aortic valve replacement
Conditions studied
- Aortic Stenosis — all drugs for Aortic Stenosis →
- Aortic Insufficiency — all drugs for Aortic Insufficiency →
- Aortic Regurgitation — all drugs for Aortic Regurgitation →
Sponsor
JenaValve Technology, Inc.
Who can join
Eligibility, any sex, with Aortic Stenosis or Aortic Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this registry is to observe longterm performance and safety of the JenaValve TAVI system, in routine medical and everyday conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01598844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcatheter aortic valve replacement
Trials testing the same drug.
- NCT07532317 — A Prospective, Multinational, Multicentre, Open-label, Randomized Trial to Evaluatesafety and Effectiveness of Meril's M · NA · not yet recruiting
- NCT06924151 — Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients · NA · recruiting
- NCT06743568 — Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation · NA · recruiting
- NCT06589063 — Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis · recruiting
- NCT06257043 — Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients · recruiting
Other recruiting trials for Aortic Stenosis
Currently open trials in the same condition.
- NCT07197736 — DELINEATE-Prospective · recruiting
- NCT07230964 — Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacemen · NA · recruiting
- NCT07205068 — Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and P · NA · recruiting
- NCT07052071 — Impact of Transcatheter Aortic Valve Implantation (TAVI) on the Gut Microbiota in Patients With Aortic Valve Stenosis · recruiting
- NCT07144189 — AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography · recruiting
Other JenaValve Technology, Inc. trials
Trials by the same sponsor.
- NCT02732704 — THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01598844 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by JenaValve Technology, Inc.
- Last refreshed: 24 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01598844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing